Welcome to our dedicated page for Profound Med SEC filings (Ticker: PROF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating trial cost breakouts or FDA milestones inside Profound Medical’s dense disclosures can feel like performing surgery without imaging. The company’s filings span hundreds of pages, packed with technical language on MRI-guided ultrasound, device margins, and reimbursement pathways—details investors can’t afford to miss.
Stock Titan solves this complexity. Our AI instantly turns the Profound Medical annual report 10-K simplified, Profound Medical quarterly earnings report 10-Q filing, and every Profound Medical 8-K material events explained notice into clear, concise summaries. Need real-time alerts? The platform streams Profound Medical Form 4 insider transactions real-time so you spot buying or selling minutes after executives act.
Here’s what you’ll uncover:
- Clinical trial spending trends and revenue from disposable probes in the 10-K
- Quarter-over-quarter adoption metrics in each 10-Q, paired with Profound Medical earnings report filing analysis
- Board incentives inside the Profound Medical proxy statement executive compensation
- Insider confidence through Profound Medical executive stock transactions Form 4
Every document—whether it’s an 8-K on a new distribution agreement or the latest S-3 prospectus—lands on this page the moment EDGAR releases it. Our AI-powered summaries, keyword search, and side-by-side financial tables mean Profound Medical SEC filings explained simply are just a click away. Stop scrolling line by line and start understanding Profound Medical SEC documents with AI.
Profound Medical Corp. filed a preliminary Form S-3 shelf registration to offer, from time to time after effectiveness, up to $150,000,000 of securities. The shelf covers common shares, warrants, debt securities, subscription receipts, and units, with specific terms and pricing to be set in future prospectus supplements.
Sales may occur through underwriters, dealers, agents, directly to investors, or via methods such as at-the-market or equity line transactions, as described in the plan of distribution. Net proceeds will be used for working capital, capital expenditures, and general corporate purposes, and may include investments or acquisitions noted in future supplements.
The company’s common shares trade on Nasdaq as “PROF” and on the TSX as “PRN”; on November 12, 2025, closing prices were $6.47 (Nasdaq) and C$9.05 (TSX). Shares outstanding were 30,193,592 as of the date of this prospectus.
Profound Medical Corp. reported Q3 2025 results and highlighted liquidity risks. Revenue rose to $5.289 million, up 87% year over year, driven by U.S. capital sales and higher recurring revenue. Gross margin improved to 74% from 63% as manufacturing efficiency and mix shifted toward higher‑margin systems. Net loss was $7.977 million, narrowing from $9.365 million.
For the nine months ended September 30, 2025, revenue was $10.121 million and net loss totaled $34.395 million, with operating cash outflow of $31.641 million. Cash was $24.826 million and working capital was $31.586 million as of September 30, 2025. Long‑term debt was presented as current at $4.480 million due to a projected covenant breach by June 30, 2026 under the CIBC Credit Agreement. Management disclosed substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing. As of November 13, 2025, 30,193,592 common shares were outstanding.
The company continues remediation of a previously identified material weakness in revenue recognition controls.
Profound Medical Corp. (PROF) announced it has entered into an exclusive distribution and supply agreement with Getz Healthcare for its TULSA-PRO system in Australia and New Zealand. The company disclosed the news under Regulation FD, indicating a commercial channel partner will handle market distribution in these regions.
The announcement was provided via a press release furnished as Exhibit 99.1. As furnished information under Item 7.01, it is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Profound Medical Corp. (PROF) announced it entered into an exclusive distribution and supply agreement in Saudi Arabia with Al Faisaliah Medical Systems Co. covering its TULSA-PRO and Sonalleve technologies. The company disclosed the news via a press release furnished under Item 7.01 (Regulation FD).
The agreement designates a single distributor for these systems in Saudi Arabia, signaling a focused commercial pathway for Profound Medical’s prostate ablation (TULSA-PRO) and MR-guided therapeutic ultrasound (Sonalleve) platforms in that market. The press release was furnished as Exhibit 99.1.
Profound Medical Corp. reported under Regulation FD that it has regained exclusive distribution rights for its TULSA-PRO product in Canada from Knight Therapeutics Inc. The company announced the change in a press release dated November 10, 2025, which is furnished as Exhibit 99.1.
The Item 7.01 disclosure notes the press release is furnished, not filed, and is not incorporated by reference into other SEC filings.
FAQ
What is the current stock price of Profound Med (PROF)?
What is the market cap of Profound Med (PROF)?
